Cancer Research UK, a company limited by guarantee and a registered charity, is governed by a Council of Trustees, the Charity’s board of directors.
The Council of Trustees is led by the Chair, Professor Sir Leszek Borysiewicz.
We maintain a register of interests and in line with Charity Commission guidance, this is available upon request from the Company Secretary (email@example.com）。请参阅右下角的链接，以下载我们的协会条款。
Professor Sir Leszek BorysiewiczFRS MA PhD FRCP FMEDSCI（椅子）
Appointed 2016. Professor Sir Leszek Borysiewicz was appointed as a Trustee in July 2016 and as Chair in November 2016. Following a distinguished academic and clinical research career and prior to his appointment as Vice-Chancellor at the University of Cambridge in 2010 until 2017, Sir Leszek’s roles included Chief Executive of the Medical Research Council and Deputy Rector of Imperial College London. He was also a founding Fellow of the Academy of Medical Sciences. His work in vaccines included Europe’s first trial of a therapeutic vaccine for human papillomavirus to treat cervical cancer, research conducted at the University of Cardiff and funded by Cancer Research UK. He also serves on the board of UKRI and the governing board of The Courtauld Institute of Art. He was knighted in 2001 for his pioneering work in vaccines.
Tracy De GrooseLLB（副主席）Appointed 2018.Tracy de Grose在创意产业的领导角色中具有广泛的营销和商业经验。 Until recently, Tracy was chair of Newsworks, the marketing arm for the UK news publishing industry. Prior to that Tracy was chief executive of Dentsu UK & Ireland with P&L responsibility for over 20 media, digital and data businesses and 4,000 people, working with a diverse range of clients including Disney, Diageo, Asda and the UK government. In 2020, Tracy founded ‘Brilliant Misfits' to advise the next generation of business leaders and entrepreneurs to help accelerate positive change. Tracy prioritises time to mentor, support and guide emerging talent and was invited to join the World Economic Forum's innovation and entrepreneurship council 2015-2017.
巴奥AdelajaAppointed 2021.Bayo Adelaja is Founder and CEO of the open innovation racial justice organisation Do it Now Now,与英国议会，ASOS，Google的初创公司，宗旨以及Bill and Melinda Gates基金会的合作，以支持服务不足的社区。她目前还在皇家志愿服务局的人民和薪酬委员会中担任人民和薪酬委员会，为制定关键的反种族主义和包容策略的发展提供建议，以增强整个慈善机构的利益相关者的能力。Bayo在达勒姆大学（Durham University）阅读英语文学时，建立了她的第一家技术初创企业。毕业后，她担任议会助理的角色，成为当时在下议院工作的最年轻的专业人士。她继续在伦敦经济学和政治科学学院分别完成了健康，人口和社会以及文化和社会的硕士学位。Bayo还坐在访问权限上 - 社会投资灵活的财务投资委员会基金会，是Prince Trust International和London Center的受托人。在2020年，她被伦敦市长的前进运动认可为支持该市商业社区的前五名人物之一。
Catherine BrownLLB(Hons)任命2015年。 Catherine Brown has broad experience in strategy and organisational change, having previously been Group Strategy Director of Lloyds Banking Group, Executive Director HR of the Bank of England, and Chief Operating Officer of Apax Partners. She is a non-executive director and chair of the remuneration committees of Metro Bank plc and QBE (UK) Ltd. She sits on the board of FNZ (UK), a private equity backed financial services technology company, and is Chairman of Additive Flow Ltd. Catherine was a non-executive board member of the Cabinet Office until March 2020.She is a trustee of Blue Cross and also has charity projects across the Himalayan region. She spent her early career as a banker before joining McKinsey and subsequently ran her own management consultancy for five years before moving into private equity at Apax Partners.
彼得·查布雷Appointed 2016.Peter查姆布雷是癌症研究技术有限公司的主席，他是开发新的癌症免疫疗法治疗的公司英国癌症研究的商业化部门。188金宝搏app亚洲 He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006. Peter is a Director of Our Future Health.
Dr Robert EastonBSC ARCS DPHIL FCGI(Treasurer)
Appointed 2020.罗伯特·伊斯顿（Robert Easton）博士是全球替代资产管理公司Carlyle的前合伙人。在该公司的19年中，他担任投资专业人士的许多职务，在多个投资组合公司董事会任职时担任收购和技术投资的基金负责人。 Robert is a past Chairman of the British Venture Capital Association and a serial investor in technology driven, small and start-up businesses. He has had a variety of engagements with the higher education sector at Oxford University, where until recently he was a Pro-Vice-Chancellor, as well as at Imperial College. In addition to being a Trustee of CRUK, Robert is a Fellow of the British Heart Foundation and a Trustee of the Young Vic Theatre and funds causes in science, sport, music, higher education, conservation and sub-Saharan Africa.
Professor Nic JonesPhD FMedSci
Appointed 2020.Professor Nic Jones is currently Director of Strategic Initiatives at the Manchester Cancer Research Centre (MCRC), a partnership between Cancer Research UK, the Christie NHS Foundation Trust and the University of Manchester. He was Director of the MCRC for 12 years from its inception in 2006 and oversaw its development into one of the foremost comprehensive cancer centres in Europe. In addition, from 2011-2016, Nic was the CRUK Chief Scientist with responsibility for overseeing the scientific strategy of the organisation. Nic was also previously the Director of the CRUK Manchester Institute and led a research team investigating specific signalling pathways implicated in cancer development and growth.
Professor Pamela Kearns博士学位Appointed 2021.帕梅拉·科恩斯（Pamela Kearns）教授是伯明翰大学临床小儿肿瘤学主席，也是伯明翰妇女和儿童医院的名誉顾问儿科肿瘤学家。她是伯明翰大学癌症与基因组科学研究所的主任，也是英国癌症研究临床试验部（CRCTU）的主任。188金宝搏app亚洲作为CRCTU的主任，她领导了英国最大的癌症试验部门之一的研究策略，为所有儿童，年轻人和成人提供了广泛的癌症的试验组合，由100多种多中心和国际癌症试验。 She was elected President of the European Society of Paediatric Oncology (SIOP Europe) in 2019, having been a Board member since 2013. She has several European roles including Executive Board Member of the academic consortium ‘Innovative Therapeutics in Childhood Cancer’ (ITCC), Chair of ITCC’s European Sponsor Institutions Committee and Steering Committee member of the International multi-stakeholder platform ‘ACCELERATE’. Her research interests are focussed on drug development and innovation of design and delivery of clinical trials for childhood cancers. She was also a Senior Clinical Advisor to Cancer Research UK from 2015 to 2020 and is a Trustee of a Child of Mine, a charity dedicated to supporting bereaved parents.
布鲁斯·庞德爵士教授FRCP FMEDSCI FRS任命2015年。布鲁斯·庞德爵士（Sir Bruce Ponder）教授是剑桥的肿瘤学名誉教授，也是英国癌症研究所的高级小组负责人。188金宝搏app亚洲他曾是李卡·斯舍（Li Ka Shing）肿瘤学教授，癌症研究所剑桥研究所和剑桥癌症中心的创始董事，以及哈奇森/MRC研究中心的联合主任和遗传流行病学的188金宝搏app亚洲Strangeways Research Laboratories。布鲁斯·庞德（Bruce Ponder）在伦敦接受了内科培训，然后在ICRF（现为弗朗西斯·克里克学院（Francis Crick Institute））获得了博士学位。他在哈佛大学达纳·法伯癌症研究所接受过医学肿瘤学培训。他的临床和研究生涯是对癌症易感性的遗传学。在过去的20年中，他领导了剑桥新的实验室和临床临床中心的发展。里程碑是1997年建立了遗传流行病学实验室，2001年的和记和MRC研究中心，2007年的CRUK剑桥研究所，并于2015年将剑桥称为CRUK大型癌症中心。for ‘services to medicine’.
Professor Sir Mike RichardsCBE MD FRCP FRCR (Hon) FRCPath (Hon) FRCSEd (Hon)Appointed 2017.迈克·理查兹爵士（Mike Richards）爵士于2013年7月被任命为护理质量委员会（CQC）的第一任医院首席检查员。卫生部主任（1999-2013）。在这些任命之前，他曾是Guy's和St Thomas的NHS Trust（1986-1995）的医学肿瘤学顾问和读者，也是姑息医学教授（1995-1999）。他于2001年被任命为CBE，并于2010年因“医学服务”而被任命为骑士Batchelor。最近，他领导了NHS英格兰的两项重大评论，一项关于成人筛查服务（2019年），第二项有关NHS诊断服务的评论（2020年）。
乔安妮·肖Appointed 2020.广泛的乔安妮·肖是一位合格的会计师commercial, public and third sector background. Aspast Chair of NHS Direct, she has a particular interest in the use of mobile and digital channels for health and medicines,以及个人，自己的健康和医疗保健提供者之间的关系不断变化。 She is currently a director of Vitality, the shared value insurance provider and Chair Designate (from November 2021) of the Royal College of Paediatrics &Child Health. She has chaired the Audit and Risk Committees of NHS England, the National Audit Office and the Money Advice Service. Past non-executive positions include Deputy Chair of Nuffield Health and Chair of the British Equestrian Federation.
Professor Moira WhyteOBE PhD FRCP FRCPE FMedSci FRSE
Appointed 2020.莫伊拉·怀特（Moira Whyte）教授是副校长，兽医学院院长，爱丁堡大学的约翰·克罗夫顿爵士呼吸医学教授。她曾担任爱丁堡炎症研究中心MRC/MRC/爱丁堡医学院院长。她是MRC战略委员会的成员，也是MRC培训和职业集团的主席，也是英国研究卓越框架（Ref）2021的Sub-Panel 1（临床医学）主席。在慢性肺部疾病的背景下，她的研究兴趣是先天免疫的基本机制。
If you require further information or have any comments please get in touch.